Dyslipidemia in FQHC’s: Rising to the Challenge

Please review the entire page to register for this activity.

Release Date: March 16, 2015
Expiration Date: April 16, 2015

Program Format: Internet Live Multimedia

Fee
There is no fee associated with this activity.

Activity Description:
The Southeast Lipid Association (SELA) in collaboration with the National Lipid Association (NLA) and Virginia Community Healthcare Association (VCHA) are offering a free webcast with live Q&A session. This program will discuss new cholesterol guidelines and dyslipidemia management in underserved populations. Through case-based discussion, the presenters will highlight the importance of Federal Qualified Health Clinics (FQHC) in the treatment and management of dyslipidemia.

Speakers:
Franklin J. Zieve, MD, PhD
Associate Chief of Staff for Research and Development
McGuire VA Medical Center
Richmond, VA

Dave L. Dixon, PharmD, BCPS, CDE, AACC, FNLA
Assistant Professor, Ambulatory Care
Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University
School of Pharmacy
Richmond, VA

Learning Objectives:
At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.
At the conclusion of this activity, all participants should be able to:

• Outline current patient guidelines for the diagnosis, management, and treatment of dyslipidemia;
• Recognize the role of drug therapy in the management of dyslipidemia;
• Review the efficacy and safety of statins and non-statin therapies;
• Implement strategies for management of dyslipidemia in special populations;
• Apply guidelines into daily practice to help patient reach goals;
• Identify contributing factors of non-adherence to lipid-lowering therapies.

 

Monday, March 16
7:00- 7:45 PM	The New Cholesterol Guidelines: Has the World Turned Upside Down?	Frank J. Zieve, MD, PhD
7:45- 8:00 PM	Question & Answer
8:00- 8:45 PM	Dyslipidemia Management in Underserved Populations: A Case-Based Discussion	Dave L. Dixon, PharmD, FNLA
8:45- 9:00 PM	Question & Answer

 

CME credit provided by the National Lipid Association
PHYSICIANS
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Lipid Association designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

DIETITIANS
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 2 Continuing Professional Education Unit (CPEUs) for completion of this activity. CDR Accredited Provider #NL0002.

CE Credit provided by Postgraduate Institute for Medicine
PHARMACISTS

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Universal Activity Number 0809-9999‐15‐092‐L01‐P(Application)

Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education.

NURSING
This educational activity for 2.0 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CRITERIA FOR SUCCESS
In order to receive credit, participants should take part in the live audio conference, complete and submit an evaluation. Certificates will be available for download after participants have complete and submit an evaluation. If you have questions about this CME activity, please contact NLA at cme@lipid.org.Please claim credit by April 16, 2015. For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Estimated time of completion: 120 minutes.

COMMERCIAL SUPPORT
There is no commercial support for this activity.

Faculty Disclosures:

Dave L. Dixon, PharmD, BCPS, CDE, AACC, FNLA
Speaking: sanofi-aventis U.S.

Franklin J. Zieve, MD, PhD
Research: AstraZeneca; Boehinger- Ingleheim; Eli Lilly; Genkyotex; Johnson & Johnson; Novartis; NovoNordisk

PLANNERS DISCLOSURES
NLA: Nothing to disclose
PIM: PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Judi Smelker-Mitchek, RN, BSN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

Copyright 2015, by the National Lipid Association, Jacksonville, FL. All rights reserved.

System Requirements
To view this educational activity you will need a JavaScript enabled web browser (Google Chrome, Firefox version 3.0 or greater OR Internet Explorer version 8.0 or greater recommended) with Browser Cookies enabled and Adobe Flash^TM version 9.0 or greater.

Registration:
Please register for Dyslipidemia in FQHC’s: Rising to the Challenge on March 16, 2015 7:00 PM EST by clicking Here.